Gilead Sciences Inc.(GILD)

$65.84 (As of 01/09/20)

Price Target (6-12 Months): **$70.00**

Long Term: 6-12 Months	**Zacks Recommendation:** (Since: 07/02/19) Prior Recommendation: Outperform	**Neutral**
Short Term: 1-3 Months	**Zacks Rank:** (1-5)	**2-Buy**
	Zacks Style Scores:	VGM:B
	Value: A | Growth: C | Momentum: B	

Summary

Gilead's HIV franchise maintains momentum on the continued uptake of Genvoya and Odefsey, and the strong uptake of Biktarvy. The company has shifted focus to the HIV franchise and newer avenues like CAR-T therapy due to a massive decline in HCV franchise sales. Label expansion of HIV therapies should boost sales. Meanwhile, the company is signing deals with other companies to strengthen its pipeline for the inflammation market. Gilead's collaboration with Novo Nordisk for NASH treatments is a step in the right direction, given its recent debacles. However, the HIV franchise is facing stiff competition from Glaxo. Moreover, the uptake of Yescarta hasn't been very impressive. Shares have underperformed the industry in the past year.

Price, Consensus & Surprise

Data Overview

52 Week High-Low	**$70.50 - $60.89**
20 Day Average Volume (sh)	**6,978,075**
Market Cap	**$83.3 B**
YTD Price Change	**1.3%**
Beta	**1.11**
Dividend / Div Yld	**$2.52 / 3.8%**
Industry	**Medical - Biomedical and Genetics**
Zacks Industry Rank	**Top 24% (62 out of 254)**
Last EPS Surprise	**-0.6%**
Last Sales Surprise	**0.1%**
EPS F1 Est- 4 week change	**0.0%**
Expected Report Date	**02/03/2020**
Earnings ESP	**1.2%**
P/E TTM	**9.7**
P/E F1	**9.4**
PEG F1	**0.8**
P/S TTM	**3.7**

Sales and EPS Growth Rates (Y/Y %)



Sales Estimates (millions of $)

	Q1	Q2	Q3	Q4	Annual*
2020	5,557 E	5,647 E	5,749 E	5,855 E	22,413 E
2019	5,281 A	5,685 A	5,604 A	5,708 E	22,285 E
2018	5,088 A	5,648 A	5,596 A	5,795 A	22,127 A

EPS Estimates

	Q1	Q2	Q3	Q4	Annual*
2020	$1.73 E	$1.77 E	$1.84 E	$1.85 E	$7.01 E
2019	$1.76 A	$1.82 A	$1.75 A	$1.68 E	$7.01 E
2018	$1.48 A	$1.91 A	$1.84 A	$1.44 A	$6.67 A

*Quarterly figures may not add up to annual.

The data in the charts and tables, including the Zacks Consensus EPS and Sales estimates, is as of 01/09/2020. The reports text is as of 01/10/2020.

Overview

Headquartered in Foster City, CA, Gilead Sciences is a biopharmaceutical company, focused on developing drugs for the treatment of human immunodeficiency virus (HIV), liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. Key products include HIV/AIDS therapies like tenofovir alafenamide (TAF)-based products Genvoya, Odefsey, Descovy, Biktarvy and Truvada. Total sales from HIV franchise came in at $14.6 billion in 2018. The portfolio also includes hepatitis C virus (HCV) drugs like Harvoni and Epclusa, and HBV drug, Vemlidy. For 2018, HCV product sales were $3.7 billion compared to $9.1 billion in 2017.

In 2017, the company launched two drugs — Yescarta, the first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, and HCV drug, Vosevi. Total Yescarta sales in 2018 came in at $264 million.

Gilead has a robust late-stage pipeline that bodes well for long-term growth. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. The company has a collaboration agreement with Galapagos for the development and commercialization of the JAK1-selective inhibitor, filgotinib, for inflammatory disease indications, including rheumatoid arthritis (RA). The company acquired Kite Pharma for $11.9 billion in 2017 to enter the CAR T space. In December 2017, Gilead acquired Cell Design Labs Inc. The company has recently collaborated with Novo Nordisk to develop drugs for the treatment of NASH.



Revenues in 2018 came in at $22.1 billion, down from $26.1 billion in 2017.

Reasons To Buy:

> Gilead' strong HIV franchise should help the company maintain momentum. Newly launched products should continue to perform well, thereby driving top-line growth.

- **Strong HIV Franchise***:* Gilead is a dominant player in the HIV market. The company was the first to bring to market a single-tablet regimen (STR) for the treatment of HIV — Atripla. Additional STRs for HIV in the market include Complera/Eviplera and Stribild, among others. Meanwhile, Gilead is looking to transition the HIV portfolio to drugs with improved long-term safety profiles. The TAF-based products — Genvoya, Odefsey and Descovy — are performing well, with strong adoption in both the United States and Europe. Descovy-based regimens continue to gain share. The HIV franchise received a major boost when the FDA approved its once-daily STR, Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF), for HIV-1 infection. Biktarvy has become the number one prescribed regimen for both treatment-naïve and switch patients. Meanwhile, the FDA approved a label expansion of Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF) as a prevention option. The agency approved the treatment for a pre-exposure prophylaxis (PrEP) indication. Descovy for PrEP is indicated to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg, who are HIV-negative and at-risk for sexually acquired HIV, excluding individuals at-risk from receptive vaginal sex. The FDA had earlier also extended the indication for Truvada as PrEP to include at-risk adolescents. Approval of new therapies will further strengthen the franchise.

- **Robust Pipeline***:* Gilead has a robust pipeline, with several development programs currently underway, ranging from phase I through phase III. The company has quite a few programs targeting non-alcoholic steatohepatitis (NASH) with advanced fibrosis, including GS-9674 (FXR agonist; phase II) and GS-0976 (ACC inhibitor; phase II). Inflammation is one of the three emerging areas, and the company has been developing a pipeline targeting inflammatory diseases.

  Phase III studies on filgotinib for the treatment of RA and Crohn's disease are currently ongoing. In August 2019, the European Medicines Agency accepted the marketing authorization application (“MAA”) for filgotinib. The MAA is seeking approval of the drug as a treatment for rheumatoid arthritis in Europe. The MAA includes data from the phase III clinical program, FINCH, which comprises three studies. The company plans to submit a new drug application to the FDA for filgotinib, seeking approval for the same, by the end of the year.

- **Acquisitions and Deals to Boost Portfolio and Strengthen Pipeline***:* Gilead is looking to boost its portfolio and pipeline through deals and acquisitions. The company is also looking to expand beyond antivirals into other therapeutic areas. In January 2016, the company collaborated with Galapagos for the development and commercialization of filgotinib in inflammatory disease indications, including RA. The agreement was recently updated whereby both companies entered a 10-year global research and development collaboration. Gilead will gain access to an innovative portfolio of compounds, including six molecules currently in clinical trials, more than 20 preclinical programs and a proven drug discovery platform. The company will receive an exclusive product license and option rights to develop and commercialize all current and future programs in all countries outside Europe. Both companies have agreed to amend certain terms of the agreement to create a broader commercialization role for Galapagos in Europe.

  Gilead acquired Kite Pharma to foray into the emerging field of cell therapy. Kite is a pioneer in cell therapy having developed engineered cell therapies that express either a chimeric antigen receptor (CAR) or an engineered T cell receptor (TCR), depending on the type of cancer. The approval of lead candidate Yescarta for the treatment of refractory aggressive non-Hodgkin lymphoma, which includes diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) is a significant boost for the company. The drug was also approved in Europe. Kite also submitted a Biologics License Application (BLA) to the FDA for the investigational CAR T cell therapy, KTE-X19, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). Kite plans to submit a Marketing Authorization Application for KTE-X19 in the European Union in early 2020.

  Gilead also acquired Cell Design Labs, Inc. for $567 million in December 2017. Cell Design Labs is a leader in developing cell-based therapies, and uses its synNotch and Throttle technology platforms. These technological platforms will enhance Gilead’s cellular therapy research efforts, which Gilead acquired through Kite Pharma acquisition. Cell Design Labs is developing several pre-clinical product candidates, including CAR T and TCR therapies for prostate cancer and hepatocellular carcinoma that use the synNotch technology.

- **Boost Shareholder Value**: Gilead is making efforts to boost shareholders' value. During 2018, Gilead repaid $6.3 billion of debt, paid cash dividends of $3.0 billion and spent $2.9 billion on repurchases of 40 million shares.

Reasons To Sell:

> Weaker-than-expected performance of HCV franchise due to lower sales of Harvoni and Sovaldi is concerning. Pipeline setbacks and stiff competition remain a threat as well.

- **Share Price Performance:** Gilead's stock has underperformed the industry in the past year.

- **HCV Franchise under Pressure**: Gilead's HCV franchise continued to witness slowdown across key markets including the United States. and Europe, reflecting lower sales of Harvoni and Sovaldi as a result of competitive and pricing pressure. The franchise saw a significant plunge in sales in the last couple of years due to new competition and fewer patient starts.

- **Pipeline Setbacks***:* Gilead is no stranger to pipeline setbacks. In fact, the company has been suffering a string of pipeline setbacks since the last few years. In 2016, the company terminated the phase II and IIb studies on simtuzumab for the treatment of idiopathic pulmonary fibrosis, NASH and primary sclerosing cholangitis; phase II and II/III studies on GS-5745 for the treatment of Crohn's Disease and ulcerative colitis; phase II studies on GS-4997 for the treatment of pulmonary arterial hypertension and diabetic kidney disease; and phase II study on eleclazine for the treatment of ventricular tachycardia/ventricular fibrillation, after determining that study data showed insufficient evidence of treatment benefit. Gilead also suffered a setback with the recent failure of a late-stage study on selonsertib in patients with compensated cirrhosis (F4) due to NASH. STELLAR-4, a phase III, randomized, double-blind, placebo-controlled study (n=877), evaluated the safety and efficacy of selonsertib, which is an investigational, once-daily, oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1), in patients with compensated cirrhosis due to NASH. The failure of the STELLAR-4 study comes as a disappointment, given the significant market potential of NASH and increasing competition from the likes of Intercept Pharmaceuticals. Moreover, STELLAR-3 on selonsertib also did not meet the pre-specified week 48 primary endpoint.

- **Kite Pharma Acquisition**: While the approval of Yescarta is a significant boost for the company, CAR-T therapy is complicated and can sometimes be associated with severe side effects which can limit potential. Moreover, given the high costs of treatment and competition from Kymriah, Yescarta is not expected to contribute significantly as of now.

Last Earnings Report

Gilead's Earnings Miss Estimates in Q3, Sales Beat

Quarter Ending	09/2019
Report Date	**Oct 24, 2019**
Sales Surprise	**0.10%**
EPS Surprise	**-0.57%**
Quarterly EPS	**1.75**
Annual EPS (TTM)	**6.77**

Gilead reported mixed results for the third quarter of 2019 as earnings missed expectations while sales managed to marginally surpass the same.

The company delivered earnings of $1.75 per share in the third quarter, declining from $1.84 in the year-ago quarter and missing the Zacks Consensus Estimate by a penny.

Total revenues of $5.60 billion beat the Zacks Consensus Estimate by 0.1% and were roughly flat year over year.

HIV Franchise Maintains Momentum

Product sales came in at $5.5 billion, up 1.1% year over year.

HCV product sales declined 25.3% to $674 million, due to competitive dynamics.

HIV product sales increased 13.5% year over year to $4.2 billion, driven by higher sales volume led by the continued uptake of Biktarvy. Sales of Biktarvy were $1.2 billion, up from $386 million in the year-ago quarter and $1.1 billion in the previous quarter. It was the number one prescribed regimen for both treatment-naïve and switch patients in the United States in the quarter.

Genvoya generated sales of $978 million, down from $1.2 billion in the year-ago quarter. Descovy recorded sales of $363 million, down from $406 million in the year-earlier period, while Odefsey sales were $436 million, up from $423 million a year ago.

CAR-T therapy Yescarta (axicabtagene ciloleucel) generated $118 million in sales, up from $75 million a year ago, driven by a higher number of therapies provided to patients and its continued expansion in Europe. However, sales were down from $120 million in the previous quarter.

Other product sales — chronic hepatitis B (HBV) drugs, cardiovascular, oncology and other categories (Vemlidy, Viread, Letairis, Ranexa, Zydelig and AmBisome) — were $522 million, which decreased from $751 million in the year-ago quarter due to declines in Ranexa and Letairis sales after generic entries in 2019.

Adjusted product gross margin was 86.2% compared with 85.9% in the year-ago period. Research & development (R&D) expenses came in at $954 million, down from $844 million in the year-ago quarter. Selling, general and administrative (SG&A) expenses increased to $967 million from $852 million in the year-ago quarter.

2019 Guidance Narrowed

Gilead now expects sales of $21.8-$22.1 billion compared with the previous guidance of $21.6-$22.1 billion. Adjusted R&D and adjusted SG&A expenses are projected to be $3.7-$3.8 billion and $4.0-4.1 billion, respectively. Adjusted product gross margin is anticipated to be 85-87%.

Dividend and Share Repurchase

During the quarter, Gilead repaid $1.5 billion of debt, paid out dividends of $804 million and spent $223 million on share buybacks.

Other Updates

The FDA approved a label expansion of HIV treatment, Descovy, as a prevention option. The agency approved the treatment for the pre-exposure prophylaxis (PrEP) indication. Descovy for PrEP is indicated to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg, who are HIV-negative and at risk for sexually acquired HIV, excluding individuals at risk from receptive vaginal sex. The approval was based on the DISCOVER trial, which demonstrated that the drug is just as effective as Truvada and offers advantages in bone and renal safety parameters.

In August, Gilead and partner Galapagos' Marketing Authorization Application for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of adults with rheumatoid arthritis was validated by the European Medicines Agency. The company is on track to complete a filing in the United States by the end of the year.

Recent News

Licenses Portfolio of HIV Antibodies From The Rockefeller University - Jan 9

Gilead announced that it has licensed The Rockefeller University's portfolio of broadly neutralizing antibodies (bNAbs) against HIV, including the two clinical-stage agents — 3BNC117 and 10-1074.

Under the agreement, Gilead acquired exclusive global licenses to develop and commercialize Rockefeller's full portfolio of HIV bNAbs. Rockefeller will receive an upfront payment and is eligible to receive cumulative milestones as well as royalties on net sales. Additionally, Rockefeller will retain rights to perform non-clinical and early-stage clinical research on the portfolio of HIV antibodies.

Partners With Eisai for RA Candidate in Japan – Dec 24

Gilead announced that it has entered into an agreement with Eisai Co., Ltd for the distribution and co-promotion of its investigational, oral, selective JAK1 inhibitor, filgotinib, in Japan. The deal is pending approval.

The candidate is being evaluated for the treatment of rheumatoid arthritis (RA).
Per the terms of the deal, Gilead Japan will retain the responsibility of manufacturing and marketing approval of filgotinib, while Eisai will be in charge of product distribution in Japan in RA and other potential future indications. Both the companies will jointly commercialize the drug, if approved.

Vosevi Approved in China – Dec 20

Gilead announced today that the China National Medical Products Administration (NMPA) has approved Vosevi (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg), a once-daily, single-tablet regimen for the treatment of chronic hepatitis C virus (HCV) infection in adults without cirrhosis or with compensated cirrhosis, who have failed prior treatment with a direct-acting antiviral (DAA) therapy.

Files NDA With FDA for Filgotinib - Dec 19

Gilead announced that it has submitted a new drug application (NDA) to the FDA for JAK inhibitor candidate, filgotinib, for the treatment of adults with moderate-to-severe rheumatoid arthritis (RA). A priority review voucher was submitted with the NDA which should shorten the anticipated time for review.

Announces Top-Line Results From NASH Study - Dec 16

Gilead announced mixed top-line results from the mid-stage study on combination and monotherapy investigational treatments for advanced fibrosis (F3-F4) due to nonalcoholic steatohepatitis (NASH).

The 48-week, phase II ATLAS randomized, double-blind, placebo-controlled study evaluated the safety and efficacy of monotherapy and dual combination regimens of the nonsteroidal farnesoid X receptor (FXR) agonist cilofexor 30 mg, the acetyl-CoA carboxylase (ACC) inhibitor firsocostat 20 mg and selonsertib 18 mg in patients with advanced fibrosis (F3-F4) due to NASH.

The results showed that the investigational regimens did not lead to a statistically significant increase in the proportion of patients who achieved the primary efficacy endpoint of a ?1-stage improvement in fibrosis without worsening of NASH. Nevertheless, statistically significant improvements in multiple response measures of fibrosis and liver function were observed in patients treated with the combination of firsocostat and cilofexor compared with placebo.

Teams Up With Kiniksa, Submits BLA for CAR T Therapy – Dec 11

Kite and Kiniksa have entered a clinical collaboration to conduct a phase II, multicenter study on pipeline candidate mavrilimumab in combination with Yescarta.

The combination study will be sponsored by Kite and conducted in patients with relapsed or refractory large B-cell lymphoma.

The objective of the study is to determine the effect of mavrilimumab on the safety of Yescarta.

Concurrently, Kite announced that it has submitted a Biologics License Application (BLA) to the FDA for the investigational CAR T cell therapy, KTE-X19, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

Valuation

Gilead's shares are down 3.4% over the trailing 12-month period. Over the past year, the Zacks sub-industry is down 2.8% while the sector is up 4.9%.

The S&P 500 index is up 25.3% in the past year.

The stock is currently trading at 9.79X forward 12-month earnings per share, which compares to 143.71X for the Zacks sub-industry, 21.59X for the Zacks sector and 18.94Xfor the S&P 500 index.

Over the past five years, the stock has traded as high as 13.65X and as low as 6.28X, with a 5-year median of 9.77X. Our Neutral recommendation indicates that the stock will perform in-line with the market. Our $70.00 price target reflects 10.41X forward 12-month earnings per share.

The table below shows summary valuation data for GILD

Valuation Multiples - GILD					
		Stock	Sub-Industry	Sector	S&P 500
P/E F 12M	Current	9.79	143.71	21.59	18.94
	5-Year High	13.65	143.71	21.59	19.34
	5-Year Low	6.28	20.82	15.91	15.17
	5-Year Median	9.77	39.29	18.98	17.44
P/S F12M	Current	3.72	2.81	2.83	3.51
	5-Year High	6.03	2.92	3.8	3.51
	5-Year Low	3.11	1.99	2.42	2.54
	5-Year Median	4.04	2.52	2.93	3
P/B TTM	Current	4.02	3.9	4.52	4.47
	5-Year High	10.59	5.68	5.01	4.47
	5-Year Low	3.4	2.41	3.42	2.85
	5-Year Median	4.67	3.24	4.27	3.61

As of 01/09/2020

Industry Analysis **Zacks Industry Rank:** Top 24% (62 out of 254)

Top Peers

Pfizer Inc. **(PFE)**	Outperform
AbbVie Inc. **(ABBV)**	Neutral
Bristol-Myers Squibb Company **(BMY)**	Neutral
GlaxoSmithKline plc **(GSK)**	Neutral
Johnson & Johnson **(JNJ)**	Neutral
Merck & Co., Inc. **(MRK)**	Neutral
Novartis AG **(NVS)**	Neutral
United Therapeutics Corporation **(UTHR)**	Neutral

Industry Comparison Industry: Medical - Biomedical And Genetics

Industry Peers

	GILD Neutral	X Industry	S&P 500	ABBV Neutral	BMY Neutral	JNJ Neutral
VGM Score	B	-	-	A	A	B
Market Cap	83.30 B	188.46 M	23.94 B	133.40 B	106.64 B	382.65 B
# of Analysts	13	3	13	4	6	8
Dividend Yield	3.83%	0.00%	1.78%	4.74%	2.75%	2.61%
Value Score	A	-	-	B	A	B
Cash/Price	0.28	0.24	0.04	0.08	0.32	0.05
EV/EBITDA	8.10	-3.61	13.97	19.23	14.91	15.10
PEG Ratio	0.75	1.60	2.03	2.13	0.85	2.34
Price/Book (P/B)	4.02	3.70	3.33	NA	6.01	6.57
Price/Cash Flow (P/CF)	8.99	12.28	13.73	9.66	14.94	13.33
P/E (F1)	9.39	25.10	18.79	9.59	11.32	16.01
Price/Sales (P/S)	3.72	12.74	2.64	4.06	4.41	4.68
Earnings Yield	10.65%	-15.85%	5.32%	10.42%	8.83%	6.25%
Debt/Equity	1.11	0.02	0.72	-4.03	1.37	0.46
Cash Flow ($/share)	7.33	-1.07	6.94	9.34	4.38	10.90
Growth Score	C	-	-	A	B	C
Hist. EPS Growth (3-5 yrs)	-12.33%	17.09%	10.56%	21.99%	20.32%	9.06%
Proj. EPS Growth (F1/F0)	-0.02%	7.57%	7.49%	5.35%	29.40%	4.78%
Curr. Cash Flow Growth	-24.62%	19.71%	14.83%	33.63%	24.21%	13.87%
Hist. Cash Flow Growth (3-5 yrs)	21.29%	8.23%	9.00%	18.69%	13.59%	7.92%
Current Ratio	2.96	5.18	1.23	1.15	3.83	1.26
Debt/Capital	52.58%	3.94%	42.99%	NA	57.87%	31.62%
Net Margin	12.04%	-196.01%	11.08%	9.90%	23.53%	21.09%
Return on Equity	37.50%	-63.46%	17.16%	-155.96%	45.49%	39.81%
Sales/Assets	0.36	0.21	0.55	0.56	0.53	0.53
Proj. Sales Growth (F1/F0)	0.57%	16.69%	4.20%	8.32%	64.79%	4.23%
Momentum Score	B	-	-	A	A	B
Daily Price Chg	0.06%	0.15%	0.53%	0.77%	2.49%	0.30%
1 Week Price Chg	-1.33%	-0.90%	-0.30%	-0.56%	-2.12%	-1.01%
4 Week Price Chg	-2.65%	4.81%	1.92%	1.67%	2.36%	2.87%
12 Week Price Chg	0.94%	13.99%	6.54%	20.06%	24.86%	6.77%
52 Week Price Chg	-3.23%	-6.00%	22.58%	2.28%	37.15%	12.09%
20 Day Average Volume	6,978,075	229,370	1,580,816	6,025,762	12,079,882	5,821,398
(F1) EPS Est 1 week change	0.00%	0.00%	0.00%	0.00%	0.06%	0.00%
(F1) EPS Est 4 week change	0.04%	0.00%	0.00%	0.00%	1.92%	0.10%
(F1) EPS Est 12 week change	-1.34%	0.63%	-0.50%	0.48%	13.05%	-0.04%
(Q1) EPS Est Mthly Chg	-0.31%	0.00%	0.00%	NA	14.50%	2.81%

Zacks Stock Rating System

We offer two rating systems that take into account investors' holding horizons: Zacks Rank and Zacks Recommendation. Each provides valuable insights into the future profitability of the stock and can be used separately or in combination with each other depending on your investment style.

Zacks Recommendation

The Zacks Recommendation aims to predict performance over the next 6 to 12 months. The foundation for the quantitatively determined Zacks Recommendation is trends in the company's estimate revisions and earnings outlook. The Zacks Recommendation is broken down into 3 Levels; Outperform, Neutral and Underperform. Unlike many Wall Street firms, we have an excellent balance between the number of Outperform and Neutral recommendations. Our team of 70 analysts are fully versed in the benefits of earnings estimate revisions and how that is harnessed through the Zacks quantitative rating system. But we have given our analysts the ability to override the Zacks Recommendation for the 1200 stocks that they follow. The reason for the analyst over-rides is that there are often factors such as valuation, industry conditions and management effectiveness that a trained investment professional can spot better than a quantitative model.

Zacks Rank

The Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon. The underlying driver for the quantitatively-determined Zacks Rank is the same as the Zacks Recommendation, and reflects trends in earnings estimate revisions.

Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

Value Score	A
Growth Score	C
Momentum Score	C
VGM Score	B

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

Disclosures

This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock.The EPS and revenue forecasts are the Zacks Consensus estimates, unless indicated otherwise on the reports first page. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment.This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time.ZIR is not a broker-dealer.ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients.Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.